Skip to content

Study · Randomized controlled trial · n = 20 · 2015

6 results

Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes.

Li R, Xu W, Luo S, Xu H, Tong G, Zeng L, Zhu D, Weng J

Acta diabetologica7 Aug 2015Cited by 47 (Europe PMC)

PMID26249206 (opens in a new tab)DOI10.1007/s00592-015-0792-2 (opens in a new tab)PepBankPUB-26249206
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed diabetes, exenatide treatment reduced body weight.

    In plain wordsIn newly diagnosed diabetes, body weight decreased during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n = 20

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Weight change
    −4.7 kg
    exenatide

    Source sentences

    Summary
    Patients treated with exenatide lost body weight remarkably (-4.7 ± 0.8 kg).
    2 context sentences
    Summary · context
    The present study was a two-center, randomized, parallel-group clinical trial.
    Summary · context
    Sixty-two newly diagnosed and drug-naïve patients with type 2 diabetes were randomized to exenatide (EXE, n = 20), mixed protamine zinc recombinant human insulin lispro injection (25R; INS, n = 21) or pioglitazone (PIO, n = 21) group for a 24-week treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed diabetes, osteocalcin did not improve significantly during exenatide treatment.

    In plain wordsIn newly diagnosed diabetes, the bone marker osteocalcin did not improve significantly during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeOsteocalcin
    Study

    n = 20

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    OC change
    −0.619 ng/ml
    EXE

    Source sentences

    Summary
    In spite of the amelioration of glucose control, no significant improvement of OC, CTX or TRAcP5b was observed at week 24 (EXE: OC -0.619 ± 0.728 ng/ml, CTX 0.147 ± 0.046 ng/ml, TRAcP5b 0.302 ± 0.149 U/L;INS:
    3 context sentences
    Summary · context
    p > 0.05), as well as BMD measurement, regardless of the treatments.
    Summary · context
    The present study was a two-center, randomized, parallel-group clinical trial.
    Summary · context
    Sixty-two newly diagnosed and drug-naïve patients with type 2 diabetes were randomized to exenatide (EXE, n = 20), mixed protamine zinc recombinant human insulin lispro injection (25R; INS, n = 21) or pioglitazone (PIO, n = 21) group for a 24-week treatment.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed diabetes, CTX did not improve significantly during exenatide treatment.

    In plain wordsIn newly diagnosed diabetes, the bone marker CTX did not improve significantly during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeC-telopeptide of type I collagen
    Study

    n = 20

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    CTX change
    0.147 ng/ml
    EXE

    Source sentences

    Summary
    In spite of the amelioration of glucose control, no significant improvement of OC, CTX or TRAcP5b was observed at week 24 (EXE: OC -0.619 ± 0.728 ng/ml, CTX 0.147 ± 0.046 ng/ml, TRAcP5b 0.302 ± 0.149 U/L;INS:
    3 context sentences
    Summary · context
    p > 0.05), as well as BMD measurement, regardless of the treatments.
    Summary · context
    The present study was a two-center, randomized, parallel-group clinical trial.
    Summary · context
    Sixty-two newly diagnosed and drug-naïve patients with type 2 diabetes were randomized to exenatide (EXE, n = 20), mixed protamine zinc recombinant human insulin lispro injection (25R; INS, n = 21) or pioglitazone (PIO, n = 21) group for a 24-week treatment.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed diabetes, TRAcP5b did not improve significantly during exenatide treatment.

    In plain wordsIn newly diagnosed diabetes, the bone marker TRAcP5b did not improve significantly during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeTRAcP5b
    Study

    n = 20

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    TRAcP5b change
    0.302 U/L
    EXE

    Source sentences

    Summary
    In spite of the amelioration of glucose control, no significant improvement of OC, CTX or TRAcP5b was observed at week 24 (EXE: OC -0.619 ± 0.728 ng/ml, CTX 0.147 ± 0.046 ng/ml, TRAcP5b 0.302 ± 0.149 U/L;INS:
    3 context sentences
    Summary · context
    p > 0.05), as well as BMD measurement, regardless of the treatments.
    Summary · context
    The present study was a two-center, randomized, parallel-group clinical trial.
    Summary · context
    Sixty-two newly diagnosed and drug-naïve patients with type 2 diabetes were randomized to exenatide (EXE, n = 20), mixed protamine zinc recombinant human insulin lispro injection (25R; INS, n = 21) or pioglitazone (PIO, n = 21) group for a 24-week treatment.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed diabetes, bone mineral density did not improve significantly during exenatide treatment.

    In plain wordsIn newly diagnosed diabetes, bone density did not improve significantly during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeBone mineral density
    Study

    n = 20

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    p > 0.05), as well as BMD measurement, regardless of the treatments.
    3 context sentences
    Summary · context
    In spite of the amelioration of glucose control, no significant improvement of OC, CTX or TRAcP5b was observed at week 24 (EXE: OC -0.619 ± 0.728 ng/ml, CTX 0.147 ± 0.046 ng/ml, TRAcP5b 0.302 ± 0.149 U/L;INS:
    Summary · context
    The present study was a two-center, randomized, parallel-group clinical trial.
    Summary · context
    Sixty-two newly diagnosed and drug-naïve patients with type 2 diabetes were randomized to exenatide (EXE, n = 20), mixed protamine zinc recombinant human insulin lispro injection (25R; INS, n = 21) or pioglitazone (PIO, n = 21) group for a 24-week treatment.

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 06HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In newly diagnosed diabetes, HbA1c improved in all groups, including exenatide, without significant differences among treatments.

    In plain wordsBlood sugar improved in all diabetes treatment groups, with no significant difference between exenatide, insulin and pioglitazone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHbA1c
    Study

    n = 62

    Comparator
    Insulin and pioglitazone groups
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c change
    −2.4%
    EXE
    HbA1c change
    −2.4%
    INS
    HbA1c change
    −2%
    PIO

    Source sentences

    Summary
    At week 24, HbA1c improved in all patients (EXE:-2.4 ± 0.3 %, INS:-2.4 ± 0.3 %, PIO:-2.0 ± 0.2 %; p > 0.05 among groups).
    2 context sentences
    Summary · context
    The present study was a two-center, randomized, parallel-group clinical trial.
    Summary · context
    Sixty-two newly diagnosed and drug-naïve patients with type 2 diabetes were randomized to exenatide (EXE, n = 20), mixed protamine zinc recombinant human insulin lispro injection (25R; INS, n = 21) or pioglitazone (PIO, n = 21) group for a 24-week treatment.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.